evobrutinib

Merck KGaA drops BTK inhibitor evobrutinib, marking end of road for blockbuster dreams
Fierce Biotech
Thu, 03/7/24 - 11:34 am
Merck KZGaA
Btk inhibitors
evobrutinib
Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies
BioSpace
Wed, 12/6/23 - 10:44 am
Merck KGaA
evobrutinib
clinical trials
relapsing multiple sclerosis
MS
Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data
Fierce Biotech
Wed, 10/11/23 - 10:20 am
Merck KGaA
evobrutinib
MS
multiple sclerosis
clinical trials
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Sun, 02/23/20 - 02:00 pm
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Sat, 08/10/19 - 01:52 pm
Merck KGaA
MS
multiple sclerosis
evobrutinib
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Fri, 10/12/18 - 12:20 pm
Merck KGaA
evobrutinib
MS
multiple sclerosis
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Endpoints
Fri, 03/9/18 - 10:48 am
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib